LeMaitre Vascular exec granted dividend equivalents

Kamke Trent G reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kamke Trent G reported acquisition or exercise transactions in this Form 4 filing.

LeMaitre Vascular Inc. senior vice president of operations Trent G. Kamke reported multiple small awards of dividend equivalent rights on Dividend Equivalent Rights instruments. All seven transactions on June 4, 2026 are coded as grants or awards, reflecting compensation-related accruals rather than market purchases or sales.

Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and accrued on previously granted restricted stock unit and performance share unit awards from December 2022, December 2023, December 2024, and December 2025. The rights vest proportionately with the underlying equity awards, and there were no open-market buys or sells disclosed in this filing.

Insider Trade Summary

Grant/Award: 11.8888 shares

Grant/Award 7 txns

Insider Kamke Trent G

Role Senior V. P., Operations

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights	0.82	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.82	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	1.403	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	1.6816	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	1.8813	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	2.1306	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	3.1523	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 71.5917 contracts (Direct)

Footnotes (7)

1. F1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
2. F2. These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
3. F3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
4. F4. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
5. F5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
6. F6. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
7. F7. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Dividend equivalent rights grant: 3.1523 rights Dividend equivalent rights grant: 2.1306 rights Dividend equivalent holdings: 12.8141 rights +1 more

4 metrics

Dividend equivalent rights grant 3.1523 rights Grant on June 4, 2026 linked to common stock

Dividend equivalent rights grant 2.1306 rights Grant on June 4, 2026 linked to common stock

Dividend equivalent holdings 12.8141 rights Total derivative rights after one June 4, 2026 transaction

Price per right $0.0000 Recorded transaction price for each dividend equivalent right

Key Terms

Dividend Equivalent Rights, restricted stock unit award, performance share unit award, economic equivalent of one share

4 terms

Dividend Equivalent Rights financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

performance share unit award financial

"These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022"

economic equivalent of one share financial

"Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did LeMaitre Vascular (LMAT) report in this Form 4?

The filing shows Trent G. Kamke received several small awards of dividend equivalent rights on June 4, 2026. These rights accrued on earlier restricted stock and performance share awards and are compensation-related, not open-market stock purchases or sales.

Who is Trent G. Kamke in relation to LeMaitre Vascular (LMAT)?

Trent G. Kamke is listed as Senior Vice President, Operations at LeMaitre Vascular Inc. The Form 4 reports that he acquired dividend equivalent rights tied to prior equity awards as part of his compensation, rather than trading common shares in the open market.

What are dividend equivalent rights in the LeMaitre Vascular (LMAT) Form 4?

Dividend equivalent rights are instruments that give the holder economic value equal to dividends on one share of common stock. In this filing, each right is the economic equivalent of one LeMaitre Vascular share and is linked to existing restricted stock unit and performance share unit awards.

Were there any open-market stock purchases or sales by Trent G. Kamke in this LMAT filing?

No open-market purchases or sales are reported. All seven transactions are coded as grants or awards of dividend equivalent rights with a price per right of $0.0000, indicating compensation-related accruals rather than discretionary buying or selling of common shares.

How do the dividend equivalent rights reported for LMAT vest over time?

The dividend equivalent rights vest proportionately with their underlying equity awards. Each set of rights is tied to specific restricted stock unit or performance share unit grants made in December 2022, December 2023, December 2024, and December 2025, and follows the same vesting schedules.

Which prior equity awards generated the dividend equivalent rights in this LMAT Form 4?

The rights accrued on restricted stock unit and performance share unit awards granted on December 12, 2022, December 8, 2023, December 6, 2024, and December 10, 2025. For each grant, related dividend equivalent rights will vest in step with the original award’s vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kamke Trent G

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR , INC.

63 SECOND AVENUE

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior V. P., Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	06/04/2026		A		0.82		(1)	(1)	Common Stock	0.82	$0	10.2477	D
Dividend Equivalent Rights	(2)	06/04/2026		A		0.82		(2)	(2)	Common Stock	0.82	$0	10.2393	D
Dividend Equivalent Rights	(3)	06/04/2026		A		1.403		(3)	(3)	Common Stock	1.403	$0	11.8663	D
Dividend Equivalent Rights	(4)	06/04/2026		A		1.6816		(4)	(4)	Common Stock	1.6816	$0	12.8141	D
Dividend Equivalent Rights	(5)	06/04/2026		A		1.8813		(5)	(5)	Common Stock	1.8813	$0	10.0724	D
Dividend Equivalent Rights	(6)	06/04/2026		A		2.1306		(6)	(6)	Common Stock	2.1306	$0	10.5326	D
Dividend Equivalent Rights	(7)	06/04/2026		A		3.1523		(7)	(7)	Common Stock	3.1523	$0	5.8193	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

7. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)